Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Thyroid Cancer

Thyroid Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Thyroid Cancer

80 trials tracked for Thyroid Cancer: 7 in phase 3 or 4 and 1 with published results. The most-cited published study has 102 citations.

80Trials tracked
7Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 6 Phase 2 53 Phase 1 4 Other / NA 16
  1. Phase 3 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) Completed · 102 cited
  2. Phase 4 To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer Completed
  3. Phase 3 Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Completed
  4. Phase 3 Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment Completed
  5. Phase 3 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed
  6. Phase 3 An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer Completed
Show 44 more trials
  1. Phase 3 Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer Completed
  2. Phase 2 Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Completed
  3. Phase 2 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed
  4. Phase 2 A Study of E7080 in Subjects With Advanced Thyroid Cancer Completed
  5. Phase 2 A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile Completed
  6. Phase 2 Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology Completed
  7. Phase 2 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed
  8. Phase 2 Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer Completed
  9. Phase 2 Energy Metabolism in Thyroidectomized Patients Completed
  10. Phase 2 Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer Completed
  11. Phase 2 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed
  12. Phase 2 Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer Completed
  13. Phase 2 Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Completed
  14. Phase 2 A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer Completed
  15. Phase 2 Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer Completed
  16. Phase 2 Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer Completed
  17. Phase 2 Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer Completed
  18. Phase 2 A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer Completed
  19. Phase 2 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed
  20. Phase 2 Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Completed
  21. Phase 2 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed
  22. Phase 2 Pioglitazone in Thyroid Cancers Completed
  23. Phase 2 Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Completed
  24. Phase 2 Nivolumab Plus Ipilimumab in Thyroid Cancer Completed
  25. Phase 2 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Completed
  26. Phase 2 Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer Completed
  27. Phase 2 Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Completed
  28. Phase 2 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Completed
  29. Phase 2 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed
  30. Phase 2 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed
  31. Phase 2 Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer Completed
  32. Phase 2 REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas Completed
  33. Phase 2 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed
  34. Phase 2 Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations Completed
  35. Phase 2 Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma Completed
  36. Phase 2 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer Completed
  37. Phase 2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma Completed
  38. Phase 2 Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer Completed
  39. Phase 2 Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery Completed
  40. Phase 2 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed
  41. Phase 2 Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer Completed
  42. Phase 2 QUILT-3.006 for Recurrent Medullary Thyroid Cancer Completed
  43. Phase 2 Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) Completed
  44. Phase 2 RAD001 for Patients With Radioiodine Refractory Thyroid Cancer Completed

Showing the 50 most-cited and recently-updated of 80 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Early genomic profiling optimizes treatment selection and expands precision therapy options across thyroid cancer subtypes
Diabetes & Endocrinology Guideline
Early genomic profiling optimizes treatment selection and expands precision therapy options across thyroid cancer subtypes Targeted therapies expand options for advanced thyroid cancer
This narrative review discusses molecular profiling and targeted therapies for patients with advanced, recurrent, or radioiodine-refractory …
New review shows molecular profiling can unlock more personalized treatments for people with advanced thyroid cancer.
Frontiers Jun 6, 2026